Member Info for B2HS2L

1/2 of the quotes from Mondays RNS turned into orders - That's the %age we were told to expect, so no problem.
However, as this outbreak becomes larger, I expect the 50% conversion rate will improve a lot, simply because of the speed with which samples can be processed, < 2 Hrs.

Friday 31.01.2020 - Launch of novel coronavirus test:

"The test has been designed to run on multiple molecular testing platforms".

So tests usable on many platforms already out there.

The conversion rate will improve as the virus threat grows.
Just my 2c

Iglu,

With shift 2 now fully in place we can expect Q1 to be the best ever trading month for the business.

Wed 22.01.2020 RNS - Trading Update ".. we expect this second shift to reach full productivity by the end of H1 2020".

Don't expect too much this quarter.
They have already lost a week's production through system outage, and that will be problematic to claw back in practice.

.."Anyone else think that the warrant sales are still being cleared through"?
The effects wont dissipate for a day or two I fear.
But a strong antidote will be some news.

Quick update for you Wildfire:
"RNS - 6th December 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign's q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular diagnostic instruments has been paid in advance and takes the number of q16 instruments sold into the Asia Pacific region to over 230 units.

Assuming this is the Peoples Republic of China, and they have good results. we can expect further orders.

Wimp, - 14 is mandatory and you know it..

Latino

9) Chinese have already received 100 NCYT "genesig® q16 qPCR molecular testing instruments", from which we can expect further orders dependent upon levels of satisfaction the Chinese experienced with results.

So we are either going to experience :
1 Drip feed of share selling into any rise, possibly for Thursday and Friday to get rid of circa 6Mil shares.
2 sp buried under 6 million shares..

Happy days, - no more warrants. I'm partially out waiting for smoke to clear..

Thanks Parkez for clarification.
The issue for me though is that someone mentioned that the reason the sp crashed to < £1 was that all the shares liberated by exercising the YA II warrant were dumped into the market at once.
Trying to establish what to expect tomorrow morning if worst case they are all dumped.
Basically, are we expecting the bargain of the century, because without warrants, the picture becomes a lot more rosy..

Where's parkez when you need him..

I thought he mentioned that the problem of rapid sp reduction was due to the entire batch of warrant shares (from I believe YA II CD) had been dumped into the market at the same time, and not drip fed as per more normal practice.

If these warrant shares are not drip fed tomorrow am or Friday, is the sp outlook dire short term without some really good news?

Interested in all responses to this:

A number of people today have been discussing a joint venture.

Why won't licensing be just as valid, it would be just as quick to organise?

NCYT have invested in production facilities so we are told, but we don't know to what extent.

Could it be that the FDA like what they see, but don't think NCYT can deliver in sufficient quantity for the FDA to maintain credibility - (and just how many might they need?).

I'm sure we should be discussing licensing just as much as jv.

Posters have mentioned buy-out's, but no-one has suggested a merger, - it could happen.

Any thoughts you might share on this?

The picture is less volatile without warrants being exercised, - must have been that email I zipped over this morning, asking for clarification...:)

P-b, we're just waiting for any good news, (and there's a shortage of bad news).
Hang around, and we'll find out soon enough where the sp will gap to.

The good news concerning China is on an 08:12 post this morning re previous sales of Novacyt equipment to China.
They are experienced (presumably) in using our equipment, so unless there is a problem we are not party to, then we should definitely expect further sales to China.

That should wake your eyes up!

NOVACYT FULL YEAR 2018 RESULTS - 30 April 2019

Nowhere near enough information about warrants in this document I'm afraid.

I just emailed the company and asked if there is a web page where all outstanding warrants and associated details are made available to investors. There are a large number of RNS's that contain details of warrants, and I don't want to have to wade through them all.

I will advise any response.

Geordie,

The news we seek is on an 08:12 post this morning re previous sales of Novacyt equipment to China.
They are experienced (presumably) in using our equipment, so unless there is a problem we are not party to, then we should expect further sales to China.

I hear what you say parkez.
Will the retreating sp place the company under pressure from warrant holders to keep providing the market with info on fresh orders?
Unfortunately not I fear.

Headancer - Why not licensing?

The Chinese might have had 100 q16 units, but I'm pretty sure that some of them have been dis-assembled for reverse engineering and cloning purposes..

Morning all,

Last night (19:05) I posted an RNS dated 13 May 2019 containing prices for the "next-generation genesig® q32 qPCR molecular testing instrument"

Research has brought to light that the previous model (q16) had already been sold to China, as indicated below:

"RNS - 6th December 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign's q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular diagnostic instruments has been paid in advance and takes the number of q16 instruments sold into the Asia Pacific region to over 230 units.

The genesig® q16 is Primerdesign's proprietary molecular testing instrument which is designed to make DNA testing affordable and easy to use. The latest order comes from a new distributor recently appointed by Novacyt and the instruments will be used in clinical diagnostic markets. This new customer provides Novacyt with a potential opportunity for further significant instrument, and genesig® reagent sales in 2019.

Primerdesign has now sold over 450 q16 units since its launch in 2015. As instrument sales grow, the Company expects a pull-through effect in relation to repeat genesig® reagent sales. Reflecting this, year to date genesig® reagent sales have increased 35% versus the comparable period in 2017.

Graham Mullis, Group CEO of Novacyt, commented:

"I am very pleased to see this order from another new customer in China which helps to further reinforce our continued investment and success in the Asia Pacific region and provides additional opportunities for future instrument and reagent sales".

- End -"

This being the case, the Friday 31.01.2020 RNS states that the novel coronavirus test can be run on the q16 and q32 models:

Friday 31.01.2020 - Launch of novel coronavirus test:

"The test has been designed to run on multiple molecular testing platforms, including Primerdesign's own genesig® q16 and q32 instrument, and therefore can be used in large and small laboratories as well as remotely where necessary. The test can generate a result in less than two hours meaning that all samples can be screened quickly which could help stop the unnecessary spread of this virus."

So the Chinese have one hundred q16 model molecular diagnostic instruments in China now.

I doubt that will be near enough, but we could expect the Chinese to have had experience running the q16, and just need to puchase the coronavirus tests.
I am sure the company is assisting with their operations with these units.

So what's holding up further orders?

Gizzard posted

https://www.otcmarkets.com/stock/NVYTF/quote